

## AstraZeneca – Call For Grant Applications (CGA\_ONC\_HER2\_Breast\_2101)

<b>Submission / Review Timeline:</b>	Accepting applications until 5:00 PM EST on 8/31/2021. Internal review will be ongoing during this time period. Collaborative submissions desired.
<b>Primary Area of Focus</b>	Oncology – Women’s Cancer
<b>Therapeutic Area</b>	HER2 expression in Breast Cancer
<b>Educational Format</b>	Virtual Live with Audio and/or Video plus Enduring Component; Certified Education Credit for the Target Audience; Format to include, but not limited to, visual and kinesthetic learning styles. Examples: interactive, digital or video-based learning
<b>Educational Audience:</b>	Pathologists
<b>Total Program Budget (multi-support acceptable) :</b>	≤ \$300,000.00
<b>Request Code</b>	<b>CGA_HER2_Breast_2101</b> (add to title in CyberGrants)
<b>Expected Program Start and End Dates</b>	Fall 2021- Fall 2022
<b>Website URL</b>	<b>Grant Application:</b> <a href="http://www.astrazenecagrants.com">www.astrazenecagrants.com</a>

### The Request:

We welcome submissions for independent medical education grants (IME/CME) from educational providers who believe they can meet the high demands of a time-sensitive rapid grant submission and deployment of virtual medical education. Submitted applications should include a formal letter of request and grant proposal with needs assessment, learning objectives, agenda, and budget schedule.

### AstraZeneca, Medical Education Grants Office (MEGO):

AstraZeneca is committed to supporting quality independent medical education that meets an educational need by providing information to healthcare professionals to improve patient care and outcomes. We support education that furthers the understanding of emerging therapies based on a documented unmet need and supports the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options. Our grant support is focused on areas of high unmet need that overlap with our medical areas of interest. For more information, please visit [www.astrazenecagrants.com](http://www.astrazenecagrants.com)

### Background on HER2 IHC in Breast Cancer

Breast cancer with human epidermal growth factor receptor 2 (HER2) immunohistochemical score of 1+ or 2+ and negative in-situ hybridization (ISH) result represents the vast majority of clinically HER2-negative breast cancers, and currently does not meet the necessary criteria for HER2-targeted therapy. However, as treatment advances emerge that may have activity in this lower level of HER2 expressing patient population, potentially leading to a change in clinical interpretation of HER2 status, there exists a need to revisit and remind pathology practice on the existing guideline-defined IHC scoring practice.

Proposals may address topics that include: (1) exploring routine and complex clinical cases along the lower-spectrum of HER2 expression; (2) quality initiatives and measures that may impact or influence IHC performance across the HER2 spectrum; or (3) effective coordination and collaboration among pathologists, oncologists, and other key members of the cancer care team.

## References

Wolff AC et al. J Clin Oncol. 2018;36:2105–2122

### **Program Requirements:**

The Program must be accredited and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and the ACCME Standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.